Michael Loiacono
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael Loiacono
Earlier roles on record: Chief Accounting Officer at Marker Therapeutics, Inc. (MRKR) until June 30, 2023. Marker Therapeutics, Inc. reported in an 8-K filed July 3, 2023 that Michael Loiacono was terminated as Chief Accounting Officer, effective June 30, 2023. The proxy statement of Marker Therapeutics, Inc. reports total compensation of $566,515 for Michael Loiacono in fiscal 2023, including a base salary of $175,915. Disclosed compensation is on record for 2 fiscal years.
“Effective June 30, 2023, Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the "Company"), was separated from the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2023-06-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Marker Therapeutics, Inc. (MRKR) | former Chief Accounting Officer | $175,915 | $566,515 |
| 2022 | Marker Therapeutics, Inc. (MRKR) | former Chief Accounting Officer | $314,423 | $479,161 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.